Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2002 / Cilt: 36 - Sayı: 2

Correlation between PASI and Histopathologic score in the assessment of methotrexate efficacy in psoriasis

Psoriasiste metotreksat etkinliğinin değerlendirilmesinde PASI-Histopatolojik skor ilişkisi

Pages
110–114
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, when making the decision of therapy cessation, we should not only rely on clinical assessment, but also histopathologic evaluation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Design: Twenty-one patients with severe plaque psoriasis treated with methotrexate were included in this study.
📊
Key Findings & Data:Materials and Methods: Methotrexate was given intramuscularly, as 15 mg at the beginning, than 25 mg in a single dose weekly.
💡
Conclusion & Impact:In conclusion, when making the decision of therapy cessation, we should not only rely on clinical assessment, but also histopathologic evaluation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background and Design: Twenty-one patients with severe plaque psoriasis treated with methotrexate were included in this study. One of our aims was to determine the correlation between clinical efficacy and histopathologic changes. The other one was to determine the value of histopathologic evaluation in the decision of treatment and follow-up periods. Materials and Methods: Methotrexate was given intramuscularly, as 15 mg at the beginning, than 25 mg in a single dose weekly. PASI and histopathologic evaluation were performed before treatment, at the end of 1st and 3rd months. Histopathologic evaluation has been performed for histopathologic score. Results: At the end of the third month, pretreatment PASI score and histopathologic score decreased %93 and % 49.2, respectively. Histopathologic improvement was correlated with clinical improvement but not as good as latter. Relapse of the disease was observed in 13 patients after 4 months. In conclusion, when making the decision of therapy cessation, we should not only rely on clinical assessment, but also histopathologic evaluation. For this purpose development of histopathologic score may be beneficial in the determination of treatment period.

Özet

Metotreksat tedavisi alan plak tip şiddetli psoriasis vulgarisli 21 hasta çalışmaya alındı. Amaçlarımızdan biri, psoriasisli hastalarda metotreksatın klinik etkinliğinin histopatolojik bulgular ile korelasyonunu tespit etmekti. Diğer amacımız ise, histopatolojik değerlendirmenin, tedavi ve takip sürelerinin belirlenmesindeki önemini saptamaktı. Metotreksat başlangıçta haftalık tek doz 15 mg, sonraki haftalarda 25 mg dozda intramusküler olarak uygulandı. Histopatolojik tetkik ve PASI değerlendirmesi tedavi öncesi, 1. ve 3. ay sonunda yapıldı. Histopatolojik değerlendirme geliştirilen histopatolojik skor ile yapıldı. Tedavi öncesi PASI değeri, 3. ay sonunda % 93, tedavi öncesi histopatolojik skor, 3. ay sonunda %49.2 oranında azaldı. Histopatolojik iyileşme klinik iyileşme ile korelasyon göstermekle birlikte klinik iyileşme kadar iyi değildi. Kontrole gelen hastaların 13'ünde ortalama 4 ay sonra lezyonlarda relaps görüldü. Sonuç olarak tedavinin kesilmesine karar verilirken sadece klinik iyileşmeye bakılmaması, aynı zamanda histopatolojik kontrolün de yapılması gereklidir. Bu amaçla geliştirilecek bir histopatolojik skorun kullanılmasının tedavi süresinin belirlenmesinde faydalı olacağı kanısındayız.

🔖

Cite This Article

YILDIZ, L., AYDIN, F., TURANLI, A. Y., CANTÜRK, T., ŞENTÜRK, N. (2022). Correlation between PASI and Histopathologic score in the assessment of methotrexate efficacy in psoriasis. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 36 - Sayı: 2, 110–114. https://ajindex.com/articles/622293

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Collins P, Rogers S: The efficacy of methotrexate in psoriasis. A review of 40 cases. Clin Exp Dermatol 1992;1 7:257-260
  2. Van Dooren-Greebe RJ, Kuijpers ALA, Mulder J et al: Methot- rexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994;130:204-210
  3. Koo J, Lebwohl M: Duration of remission of psoriasis therapi- es. J Am Acad Dermatol 1999;41 (1 ):51-59 4. Van Dooren-Greebe RJ, Kuijpers ALA, Mulder J et al: Interrup- tion of log-term methotrexate treatment in psoriasis: evaluation of clinical course and laboratory parameters after discontinu- ation and reintroduction of weekly oral methotrexate. Acta Derm Venereol 1995;75:393-396
  4. Chen GS, Wu TM, Yang SA, Yu HS: Quantitative assess- ments of physiological and biological parameters in psoriatic lesions and its correlations to the clinical severity of psoriasis. Gaoxiong Yi Xue Ke Za Zhi 2001;1 7(8):408-418.